Skip to main content
. 2020 May 9;10(5):916. doi: 10.3390/nano10050916

Figure 1.

Figure 1

Schematic representation of relevant barriers that mesoporous silica nanoparticles (MSNs) have to face when administered to a patient. These barriers include potential premature release and different biological barriers, such as lack of accumulation in tumor tissues, lack of accumulation in cancer cells and sequestration in the endo-lysosomes.